Similar Search Results

Innovation for economic performance: the case of Latin American firms

Crespi, Gustavo; Arias-Ortiz, Elena; Tacsir, Ezequiel; … - In: PharmacoEconomics 4 (2014) 1, pp. 31-50

In this paper, a wide range of innovation indicators are analyzed in order to describe the innovation behavior of … Surveys define innovation rates as the share of firms introducing product and process innovations. The survey also measures … nature of the innovation process in the region. Statistics about the performance of LAC firms are provided using different …

Persistent link: https://www.econbiz.de/10011001603

Economic Burden of Irritable Bowel Syndrome: Proposed Strategies to Control Expenditures

Camilleri, Michael; Williams, Donald E. - In: PharmacoEconomics 17 (2000) 4, pp. 331-338

It has been suggested that the annual direct costs for irritable bowel syndrome (IBS) are now around $US41 billion in the 8 most industrialised countries. This paper reviews the data on calculations of direct costs. The true economic burden is unclear, as there are insufficient data on indirect...

Persistent link: https://www.econbiz.de/10005590450

Cost Effectiveness of Combination HIV Therapy: 3 Years Later

Moore, Richard D. - In: PharmacoEconomics 17 (2000) 4, pp. 325-330

Since 1997, expert panel guidelines for HIV care have recommended the use of combination antiretroviral therapy with at least 3 antiretroviral drugs. Several studies have examined the cost effectiveness of 3-drug combination antiretroviral regimens for the treatment of HIV infection. Analyses...

Persistent link: https://www.econbiz.de/10005590539

Emerging Role of Pharmacoeconomics in the Research and Development Decision-Making Process

Dimasi, Joseph A.; Caglarcan, Erol; Wood-Armany, Maria - In: PharmacoEconomics 19 (2001) 7, pp. 753-766

Objectives: This study examines the organisational structure of pharmacoeconomics departments in major pharmaceutical and biotechnology companies, the impediments to optimal use of pharmacoeconomic evaluations by companies and the integration of pharmacoeconomic analysis with research and...

Persistent link: https://www.econbiz.de/10005449023

Economic Evaluation of a New Acellular Vaccine for Pertussis in Canada

Iskedjian, Michael; Einarson, Thomas R.; O'Brien, Bernie J. - In: PharmacoEconomics 19 (2001) 5, pp. 551-563

Objective: Pertussis is a highly contagious infection affecting mainly children. Acellular pertussis vaccines were recently introduced in Canada based on evidence of improved safety and efficacy over whole cell vaccines, the current standard of care. The following study reports the economic...

Persistent link: https://www.econbiz.de/10005449092

The Economics of HIV Vaccines: Projecting the Impact of HIV Vaccination of Infants in Sub-Saharan Africa

Bos, Jasper M.; Postma, Maarten J. - In: PharmacoEconomics 19 (2001) 9, pp. 937-946

Objectives: 1. To project vaccine parameters, economic consequences and market size associated with HIV-1 vaccination of infants in sub-Saharan Africa through the Expanded Program on Immunisation (EPI); and 2. to assess threshold values for price and effectiveness. Study design and methods:...

Persistent link: https://www.econbiz.de/10005449097

Effectiveness of Eletriptan in Reducing Time Loss Caused by Migraine Attacks

Wells, Nicholas E.J.; Steiner, Timothy J. - In: PharmacoEconomics 18 (2000) 6, pp. 557-566

Background: The growing literature on the economics of migraine and its treatment generally indicates that the direct healthcare costs of managing the disorder are relatively low compared with the personal and societal burdens resulting from the disruption to normal functioning caused by...

Persistent link: https://www.econbiz.de/10005449270

Dermatan Sulfate versus Unfractionated Heparin for the Prevention of Venous Thromboembolism in Patients Undergoing Surgery for Cancer: A Cost-Effectiveness Analysis

Attanasio, Ermanno; Russo, Pierluigi; Carunchio, Gabriella - In: PharmacoEconomics 19 (2001) 1, pp. 57-68

Background: In a recent clinical trial, dermatan sulfate was found to be more effective than unfractionated heparin (UFH), but equally well tolerated, for the prevention of deep vein thrombosis (DVT) after major surgery for cancer. Objective: To perform a cost-effectiveness analysis of dermatan...

Persistent link: https://www.econbiz.de/10005243139

Cost-Effectiveness Analysis of Pneumococcal Vaccination of Adults and Elderly Persons in Belgium

De Graeve, Diana; Lombaert, Geert; Goossens, Herman - In: PharmacoEconomics 17 (2000) 6, pp. 591-601

Objective: To analyse the direct medical costs and effectiveness of vaccinating adults aged between 18 and 64 years and elderly persons =65 years of age with the 23-valent pneumococcal polysaccharide vaccine. Design and setting: This was a decision-analytic modelling study from the societal...

Persistent link: https://www.econbiz.de/10005404788

Economic Impact of Low Dose Polyethylene Glycol 3350 Plus Electrolytes Compared with Lactulose in the Management of Idiopathic Constipation in the UK

Christie, Angela H.; Culbert, Pearl; Guest, Julian F. - In: PharmacoEconomics 20 (2002) 1, pp. 49-60

Objective: To estimate the economic impact of using low dose polyethyene glycol 3350 (PEG 3350) plus electrolytes (PEG+E) compared with lactulose in the treatment of idiopathic constipation in ambulant patients. Design and perspective: This was a decision analytic modelling study performed from...

Persistent link: https://www.econbiz.de/10005404796